(Sharecast News) - Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves the majority of its Xyrem (sodium oxybate) antitrust class action cases in the US.
The settlement relates o lawsuits brought against the company by third-party payors in the US who...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE